The Effect of Extracorporeal Shock Wave Therapy in Patients With Cubital Tunnel Syndrome
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cubital Tunnel Syndrome
- Sponsor
- Tri-Service General Hospital
- Enrollment
- 7
- Locations
- 1
- Primary Endpoint
- Change from baseline of pain on 4th, 8th, 12th, 16th and 24th weeks after treatment
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The shock wave is a new and potential intervention for the reinnervation of peripheral nerve. The purpose of this study was to assess the effect of extracorporeal shock wave therapy on cubital tunnel syndrome.
Detailed Description
Investigators perform a prospective randomized, single-blinded study to investigate the effect of ESWT in patients with cubital tunnel syndrome. Patients were randomized into intervention and control group. Participants in intervention group received three-sessions of ESWT and single one session of ESWT was given in control group. The evaluation was performed pretreatment as well as on the 4th, 8th, 12th, 16th and 24 week after the treatment.
Investigators
Yung-Tsan Wu
Attending physician of physical medicine and rehabilitation
Tri-Service General Hospital
Eligibility Criteria
Inclusion Criteria
- •Age between 20-80 year-old.
- •Typical symptoms and signs of cubital tunnel, such as positive Tinel's sign numbness/tingling in at least 5th digits, and in whom the diagnosis was confirmed using an electrophysiological study.
Exclusion Criteria
- •Coagulopathy
- •Inflammation status
- •Patients who had conditions mimicking cubital tunnel syndrome, such as cervical radiculopathy, polyneuropathy, brachial plexopathy, thoracic outlet syndrome or who had previously undergone wrist surgery or steroid injection for cubital tunnel syndrome.
Outcomes
Primary Outcomes
Change from baseline of pain on 4th, 8th, 12th, 16th and 24th weeks after treatment
Time Frame: Pre-treatment, 4th, 8th, 12th, 16th and 24th weeks after treatment
Visual analog scale (VAS)
Secondary Outcomes
- Change from baseline of severity of symptoms and functional status on 4th, 8th, 12th, 16th and 24th weeks(Pre-treatment, 4th, 8th, 12th, 16th and 24th weeks after treatment)
- Change from baseline of electrophysiological study on 4th, 8th, 12th, 16th and 24th weeks(Pre-treatment, 4th, 8th, 12th, 16th and 24th weeks after treatment)